<DOC>
	<DOCNO>NCT02721264</DOCNO>
	<brief_summary>Patients NASH ( Non Alcoholic Steatohepatitis ) cirrhosis current prior histological evidence steatosis steatohepatitis admit Department Hepatology Institute Liver Biliary Sciences , meet inclusion criterion provide inform consent include study .</brief_summary>
	<brief_title>Fecal Microbiota Therapy Versus Standard Therapy NASH Related Cirrhosis .</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Age 18 year . 2 . All patient cirrhosis current previous histological evidence steatosis steatohepatitis . 3 . Histologic evidence definite probable NASH base upon liver biopsy prior enrollment NAFLD activity score ( NAS ) ≥5 ≥1 component NAS score ( steatosis , score 03 , balloon degeneration , 02 , lobular inflammation , 03 ) . 4 . No past history upper GI bleeding , ascites , hepatic encephalopathy 1 . Diagnosis liver disease NASH cirrhosis 2 . History gastrointestinal bleeding , ascites , hepatic encephalopathy 3 . Ongoing bacterial infection require antibiotic treatment . 4 . Current history significant alcohol consumption period 3 consecutive month within 1 year prior screen 5 . Treatment antibiotic probiotic precede 3 month . 6 . Inability safely obtain liver biopsy perform upper GI endoscopy 7 . Psychiatric disorder 8 . HIV 9 . Pregnant woman 10 . Patients SBP ( Spontaneous Bacterial Peritonitis ) prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>